SMEDILE, Antonina
 Distribuzione geografica
Continente #
NA - Nord America 13.355
EU - Europa 11.332
AS - Asia 5.919
SA - Sud America 297
AF - Africa 256
OC - Oceania 143
Continente sconosciuto - Info sul continente non disponibili 19
Totale 31.321
Nazione #
US - Stati Uniti d'America 12.888
CN - Cina 3.439
IT - Italia 1.913
DE - Germania 1.816
IE - Irlanda 1.215
SE - Svezia 1.209
FR - Francia 958
UA - Ucraina 824
FI - Finlandia 628
KR - Corea 567
GB - Regno Unito 541
JP - Giappone 391
DK - Danimarca 370
CA - Canada 360
PL - Polonia 353
VN - Vietnam 305
IN - India 302
AT - Austria 266
RU - Federazione Russa 264
TR - Turchia 250
ES - Italia 220
NL - Olanda 180
BR - Brasile 171
TW - Taiwan 157
BE - Belgio 143
AU - Australia 129
HK - Hong Kong 102
GR - Grecia 92
MX - Messico 81
EG - Egitto 77
RO - Romania 71
CH - Svizzera 67
ID - Indonesia 66
SG - Singapore 59
IR - Iran 49
AR - Argentina 34
CO - Colombia 32
PK - Pakistan 32
PT - Portogallo 32
PH - Filippine 30
HU - Ungheria 28
KE - Kenya 28
UZ - Uzbekistan 27
TH - Thailandia 26
CZ - Repubblica Ceca 25
NO - Norvegia 25
ZA - Sudafrica 24
HR - Croazia 23
IQ - Iraq 22
CL - Cile 21
CM - Camerun 19
MY - Malesia 19
EU - Europa 18
EC - Ecuador 15
IL - Israele 14
NZ - Nuova Zelanda 14
MN - Mongolia 13
NG - Nigeria 12
PE - Perù 12
RS - Serbia 12
MU - Mauritius 11
VE - Venezuela 11
SD - Sudan 10
SI - Slovenia 10
BG - Bulgaria 9
TN - Tunisia 9
ZM - Zambia 9
DZ - Algeria 8
MA - Marocco 8
BF - Burkina Faso 7
CU - Cuba 7
SA - Arabia Saudita 7
BY - Bielorussia 6
CR - Costa Rica 6
ET - Etiopia 6
MK - Macedonia 6
BA - Bosnia-Erzegovina 5
LV - Lettonia 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
TL - Timor Orientale 5
YE - Yemen 5
AE - Emirati Arabi Uniti 4
BD - Bangladesh 4
GM - Gambi 4
PR - Porto Rico 4
CI - Costa d'Avorio 3
CY - Cipro 3
KZ - Kazakistan 3
LB - Libano 3
LU - Lussemburgo 3
MZ - Mozambico 3
CD - Congo 2
GE - Georgia 2
JO - Giordania 2
LT - Lituania 2
LY - Libia 2
MD - Moldavia 2
NP - Nepal 2
Totale 31.293
Città #
Beijing 1.794
Chandler 1.472
Ann Arbor 1.459
Dublin 1.201
Fairfield 669
Houston 624
Villeurbanne 551
Jacksonville 517
Dearborn 488
Ashburn 463
Torino 458
Wilmington 448
Redwood City 435
Woodbridge 394
Medford 379
Princeton 376
Nyköping 325
Seattle 273
Warsaw 263
Vienna 250
Pisa 232
Shanghai 226
Cambridge 198
Guangzhou 182
Fremont 172
Dong Ket 162
Ottawa 162
Boston 139
Milan 120
Nanjing 107
Brussels 104
Boardman 103
New York 97
Rome 93
Taipei 92
Tokyo 79
Toronto 74
Verona 71
Wuhan 69
Chengdu 64
Hangzhou 62
Istanbul 53
Norwalk 53
Hefei 52
Zhengzhou 52
San Diego 51
Barcelona 46
London 46
Hanoi 44
Munich 43
Kunming 42
Chongqing 40
Jakarta 40
Seoul 40
Turin 40
Ankara 39
Nürnberg 38
Pune 38
Jinan 36
Madrid 35
Bucharest 33
Phoenix 33
Central District 32
Paris 32
Falls Church 31
Washington 31
Duncan 30
Fuzhou 30
Lachine 28
San Mateo 28
Amsterdam 27
Düsseldorf 27
Changsha 26
Mountain View 26
Silver Spring 26
Delhi 25
Hanover 25
Helsinki 24
Moscow 24
Bologna 23
Changchun 23
Hyderabad 23
Melbourne 23
Naples 23
Bengaluru 22
Berlin 22
Nanchang 22
Rotterdam 22
Tianjin 22
Nanning 21
Rochester 21
Singapore 21
Hebei 20
Saint Petersburg 20
São Paulo 20
Xian 20
Central 19
Gießen 19
Ho Chi Minh City 18
Los Angeles 18
Totale 17.255
Nome #
Serum zonulin in patients with inflammatory bowel disease: a pilot study 1.583
Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection 934
Hepatitis delta virus diagnosis. 674
Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response 594
Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma 547
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. 512
Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis 498
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study 471
Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. 396
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 336
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 336
Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin for hepatocellular carcinoma detection 335
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. 312
DURABILITY OF THE RESPONSE TO PEGINTERFERON ALFA2b AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS: A COHORT STUDY IN THE ROUTINE CLINICAL SETTING. 311
Chronic hepatitis B therapy: available drugs and treatment guidelines. 299
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 294
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 286
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 273
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents 268
Endocrine manifestations of chronic HCV infection 265
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 255
Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. 254
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 222
Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis 219
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 209
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 194
Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers 194
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 185
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 183
AISF position paper on liver disease and pregnancy. 182
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 181
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease 181
Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study 178
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B 178
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 175
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. 172
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 170
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 167
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 165
Plasma Selenoprotein P levels are related to adipose tissue insulin resistance, composition of free fatty acids and liver fibrosis in non-diabetic patients with Non Alcoholic Fatty Liver Disease 160
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 153
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients. 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
F-8 Importance of HLA-B in the sustained virological response in patients with chronic hepatitis C treated with peg-IFN and ribavirin 148
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids 145
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 144
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 144
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 143
Discordant results for IL28B genotyping (rs12979860 vs. rs8099917) and the prediction of rapid viral response in chronic hepatitis C 140
Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. 139
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
Pegylated interferon therapy of chronic hepatitis D: In need of revision 136
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 132
CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. 132
Abnormal insulin sensitivity in-chronic hepatitis C virus (HCV) infection: A link with steatosis? 131
Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic acid breath test 130
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 127
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 126
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C. 125
LIPIDOMICS REVEALS THAT LOW PLASMA UNSATURATED TO SATURATED FAT RATIOS ARE BIOMARKERS OF NAFLD AND LIVER DAMAGE 125
Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Viral Response in Patients with Genotype 1 Chronic Hepatitis C 124
Subjects with non alcoholic fatty liver disease (NAFLD) display increased visceral and pancreatic fat associated with worse metabolic profile. 124
Angiopoietin like protein 4 (ANGPTL4): a marker of alteration in lipid metabolism, insulin resistance and ectopic fat accumulation 124
Alteration in glucose metabolism after an oral glucose load and relationship with liver damage in patients with NAFLD. 123
Antibodies against GOR in patients undergoing orthotopic liver trasplantation (OLT) 122
Italian blood donors with anti-HBc and occult hepatitis B virus infection 122
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. 122
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 121
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease 121
Inhibition of chymase-dependent production of kidney angiotensin II improves renal sodium handling and prevents ascites in experimental liver cirrhosis 120
Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA 119
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients. 119
Impact of fat versus glucose load on oxidative stress in non-alcoholic fatty liver disease. 117
Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 116
Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. 115
Validation of surrogate indexes of peripheral and hepatic insulin resistance and evaluation of their utility as non-invasive predictors of histological features in patients with Non-Alcoholic Fatty Liver Disease 114
Adverse impact of visceral fat on lipid and metabolic profile in fatty liver disease 112
CLINIC EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HBV CHRONIC INFECTION 111
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. 110
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 109
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence 107
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 107
THE ROLE OF ANTI-IFI16 ANTIBODIES IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES (IBD) 107
Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. 106
Matabolomic analysis identifies new biomarkers of liver damage in NAFLD 105
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 104
The combination of Index of NASH score and liver stiffness improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with NonAlcoholic Fatty Liver Disease. 103
Oxidative stress-inducible factors promote liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease. 102
Etiological factors of chronic hepatitis in Italy: a 2014 national survey 102
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 101
DEREGULATION OF DE NOVO LIPOGENESIS CAN BE ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE 101
ETIOLOGY OF CHRONIC LIVER DISEASES IN THE NORTHWEST OF ITALY, 1998 THROUGH 2014 101
CLINICAL EVALUATION OF CIRCULATING MICRORNAS AS POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HBV INFECTION 100
Quantitative and qualitative analysis of plasma free fatty acids and their impact on liver damage in NAFLD patients. 99
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 98
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B 97
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 97
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 97
Inactive hepatitis B virus carriers: a favourable clinical condition 94
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 94
Totale 20.497
Categoria #
all - tutte 70.443
article - articoli 0
book - libri 0
conference - conferenze 23.509
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.952


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.297 0 0 0 0 0 0 0 0 149 315 575 258
2019/20205.022 213 184 262 548 400 809 521 362 499 534 347 343
2020/20213.899 407 317 294 242 359 257 312 179 377 331 307 517
2021/20225.120 232 273 280 451 362 303 408 397 317 483 809 805
2022/20235.561 592 408 190 467 446 1.238 571 361 540 215 323 210
2023/20242.176 369 434 195 210 191 363 163 225 26 0 0 0
Totale 32.615